Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had a CT scan as part of their care
- People who have been found to have small spots or growths on their lungs (called pulmonary nodules)
- People whose doctors have decided that surgery is the right treatment for them
- People who have received clear results from a tissue or biopsy test confirming their diagnosis
- People whose medical records and health information are complete and available
Who may not be able to join:
- People who do not have CT scan results on file
- People who have declined or refused surgical treatment
- People who do not have a confirmed diagnosis from a tissue or biopsy test
- People who have a blood-borne infectious disease, such as HIV, hepatitis B, or hepatitis C
- People whose cancer or condition requires urgent, immediate treatment
- People with poor or difficult-to-access veins (confirm with trial site)
- People whose blood does not clot normally, or who are currently taking blood-thinning or clot-dissolving medications
- People with a psychiatric condition or serious mental illness
- People who have difficulty communicating or who would not be able to attend follow-up appointments over time
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-0512-67972216
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Changes in peripheral blood immune indicators, differences in radiomics and clinicopathological characteristics; Tumor antigen-specific T cells were detected by flow cytometry or single-cell sequencing to determine the differences in the immune microenvironment between patients with benign pulmonary nodules and those with malignant pulmonary nodules.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.